Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum
Globe Newswire (Wed, 16-Sep 8:30 AM ET)
Equillium to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 8:30 AM ET)
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Equillium Secures $35 Million Financing from RA Capital, Extends Cash Runway to 2029
Market Chameleon (Fri, 13-Mar 7:08 AM ET)
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Equillium trades on the NASDAQ stock market under the symbol EQ.
As of September 28, 2026, EQ stock price climbed to $1.70 with 162,854 million shares trading.
EQ has a beta of 0.42, meaning it tends to be less sensitive to market movements. EQ has a correlation of 0.00 to the broad based SPY ETF.
EQ has a market cap of $107.79 million. This is considered a Micro Cap stock.
In the last 3 years, EQ traded as high as $3.54 and as low as $.27.
The top ETF exchange traded funds that EQ belongs to (by Net Assets): VTI, VXF, IWC, AVSC, QQQS.
EQ has outperformed the market in the last year with a return of +21.4%, while the SPY ETF gained +17.8%. However, in the most recent history, EQ shares have underperformed the stock market with its stock returning -42.4% in the last 3 month period and -19.4% for the last 2 week period, while SPY has returned +4.8% and +0.7%, respectively.
EQ support price is $1.57 and resistance is $1.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EQ shares will trade within this expected range on the day.